Cytek Biosciences, Inc. (CTKB) is a publicly traded company in the Unknown sector. Across all available filings, 19 corporate insiders have executed 408 transactions totaling $111.2M, demonstrating a bullish sentiment with $89.5M in net insider flow. The most recent transaction on Feb 18, 2026 involved a transaction of 1,346 shares valued at $0.
No significant insider buying has been recorded for CTKB in the recent period.
No significant insider selling has been recorded for CTKB in the recent period.
Based on recent SEC filings, insider sentiment for CTKB is bullish with an Insider Alignment Score of 90/100 and a net flow of $89.5M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Cytek Biosciences, Inc. (CTKB) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 19 insiders are actively trading CTKB stock, having executed 408 transactions in the past 90 days. The most active insider is Peter Kolchinsky (Executive), who has made 5 transactions totaling $50.1M.
Get notified when executives and directors at CTKB file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | Option Exercise | 1,346 | $N/A | $0 | |
| Feb 18, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | Payment | 525 | $4.20 | $2.2K | |
| Feb 18, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | Option Exercise | 1,346 | $N/A | $0 | |
| Nov 18, 2025 | Chin Richard | Executive | Option Exercise | 6,107 | $N/A | $0 | |
| Nov 18, 2025 | Holder Michael | Executive | Option Exercise | 2,181 | $N/A | $0 | |
| Nov 18, 2025 | Jiang Wenbin | Executive | Option Exercise | 29,002 | $N/A | $0 | |
| Nov 18, 2025 | Jiang Wenbin | Executive | Payment | 8,697 | $5.53 | $48.1K | |
| Nov 18, 2025 | Jiang Wenbin | Executive | Payment | 11,413 | $5.53 | $63.1K | |
| Nov 18, 2025 | Jiang Wenbin | Executive | Option Exercise | 22,100 | $N/A | $0 | |
| Nov 18, 2025 | Jiang Wenbin | Executive | Payment | 4,636 | $5.53 | $25.6K | |
| Nov 18, 2025 | Jiang Wenbin | Executive | Option Exercise | 11,781 | $N/A | $0 | |
| Nov 18, 2025 | Jiang Wenbin | Executive | Payment | 2,660 | $5.53 | $14.7K | |
| Nov 18, 2025 | Jiang Wenbin | Executive | Option Exercise | 6,758 | $N/A | $0 | |
| Nov 18, 2025 | D. Mccombe William | Executive | Option Exercise | 13,051 | $N/A | $0 | |
| Nov 18, 2025 | D. Mccombe William | Executive | Payment | 4,196 | $5.53 | $23.2K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 26 | $100.3M | 88.9% |
Sale(S) | 75 | $10.9M | 9.6% |
Payment(F) | 140 | $1.5M | 1.3% |
Exercise(M) | 154 | $130.4K | 0.1% |
Gift(G) | 6 | $0 | 0.0% |
Conversion(C) | 7 | $0 | 0.0% |
Insiders at Cytek Biosciences, Inc. are accumulating shares at an accelerated pace. With 19 insiders making 408 transactions totaling $100.3M in purchases versus $10.9M in sales, the net buying activity of $89.5M signals strong executive confidence. Peter Kolchinsky (Executive) leads the buying activity with $50.1M in transactions across all time.